The company will work with university researchers to evaluate its predictive immune modeling technology in personalizing the use of immune checkpoint inhibitors.
The biopharma company is evaluating its experimental immunotherapy against HPV-positive cancers alone and in combination with a bifunctional fusion protein.
A Sanford Cancer Center team is genomically profiling head and neck squamous cell cancer samples to look for biomarkers of immunotherapy and chemoradiation response.
Researchers will use the funds to explore if the device can deplete circulating exosomes and make head and neck cancer patients more responsive to treatments.
Preclinical studies showed that combining CUE-101 with an anti-PD1 checkpoint inhibitor could increase anti-tumor efficacy in advanced HPV-positive head and neck tumors.
